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Introduction: Thromboembolic complications contribute substantially to perioperative morbidity and mortality.
Routine laboratory tests do not detect patients with acquired or congenital hypercoagulability who may be
at increased risk of perioperative thromboembolism. Rotational thromboelastometry (ROTEM) is a digitized
modification of conventional thromboelastography that is stable and technically easy to use. We designed a
prospective observational study to evaluate whether preoperative ROTEM can identify patients at increased risk
for postoperative thromboembolic complications after major non-cardiac surgery.
Methods: Preoperative ROTEM analysis using extrinsic rotational thromboelastometry (EXTEM), intrinsic rotational
thromboelastometry (INTEM), and fibrinogen rotational thromboelastometry (FIBTEM) activators was performed on
313 patients undergoing major non-cardiac surgery. Patients’ medical records were reviewed after discharge for
results of standard coagulation studies - partial thromboplastin time (PTT), international normalized ratio (INR), platelet
count - and evidence of thromboembolic complications during their hospital stay. A thromboembolic complication was
defined as a new arterial or deep venous thrombosis, catheter thrombosis, or pulmonary embolism diagnosed by
ultrasound or spiral chest computed tomography.
Results: Ten patients developed postoperative thromboembolic complications, of whom 9 had received standard
prophylaxis with subcutaneous enoxaparin or heparin. There was no indication of by PTT, INR, or platelet count.
Preoperative EXTEM and INTEM activators that assess fibrin clot formation and platelet interaction indicated that
these patients had significantly lower clot formation time (CFT) and significantly higher alpha angle (α) and
maximum clot firmness (MCF), compared to patients without thromboembolic complications. There was no
significant difference for any parameter using FIBTEM activator, which excludes platelet interaction. Receiver
operating characteristic (ROC) curves were constructed for these variables. INTEM clot firmness at 10 min (A10)
was the best predictor of thromboembolic complications, with an ROC area under the curve of 0.751.
Conclusions: Our results indicate that preoperative ROTEM assays that include fibrin clot and platelet interaction
may detect patients at increased risk for postoperative thromboembolic complications after major non-cardiac
surgery. Future studies need to evaluate the clinical utility and cost effectiveness of preoperative ROTEM and better
define the association between ROTEM values and specific hypercoagulable conditions.* Correspondence: gw72@columbia.edu
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Thromboembolic complications of surgery such as deep
vein thrombosis and pulmonary embolism induce substan-
tial postoperative morbidity and mortality [1]. Postopera-
tive anticoagulation to prevent these complications may in
its turn increase morbidity by inducing major bleeding [2].
Certain patient and operative characteristics are known
to predispose patients to postoperative thromboembolic
events [3], and complex scoring systems have been devel-
oped to detect patients at increased risk [4]. However,
neither scoring systems nor routine coagulation tests de-
tect patients with acquired or congenital hypercoagulable
states. For example, up to 8% of the European population
is heterozygous for Factor V Leiden [5]. These patients are
at increased risk for thromboembolic complications, but
are not easily identified prior to surgery. The development
of a single, readily available test to identify patients at
increased risk for postoperative venous thromboembolism
could provide early identification, guide more effective
thromboembolic prophylaxis, and result in improved peri-
operative outcomes.
Rotational thromboelastometry (ROTEM) is a modular,
computerized point-of-care system that is based upon a
modification of the principles of thromboelastography
(TEG). ROTEM utilizes a variety of activators to provide a
targeted and dynamic analysis of specific aspects of the
coagulation cascade [5]. As such, ROTEM can provide a
more detailed evaluation of clot formation and breakdown
in the individual patient and can identify specific cascade
abnormalities. The present study was designed to
determine the ability of preoperative ROTEM analysis to
predict postoperative thromboembolic complications in
patients undergoing major non-cardiac surgery.
Materials and methods
Study design and subjects
All adult patients undergoing major non-cardiac surgery
at Columbia University Medical Center were eligible for
enrollment. We only used blood that was to be discarded
during clinically indicated blood draws. The Columbia
University Institutional Review Board (IRB) approved this
study and waived the requirement to obtain written
preoperative consent. In accordance with US Federal
Guidelines, it considered the risk of this study minimal
and agreed that the study could not practicably have been
carried out without a waiver of consent. All patients or
their surrogates received an information sheet after sur-
gery to inform them about this study.
Major surgery was defined as any elective non-cardiac
surgical procedure that was likely to require inpatient
admission for more than three days, as well as the intraop-
erative placement of an arterial catheter for blood draws.
Patients were the first cases each day in the operating
rooms, randomly selected with no specific randomizationscheme. History of past or current thromboembolism
prior to surgery did not exclude patients from the study,
but persistence of a known preoperative condition was
not considered a positive postoperative thromboembolic
event. A thromboembolic complication was defined as a
new arterial or deep venous thrombosis, catheter throm-
bosis, or pulmonary embolism diagnosed by ultrasound or
spiral computed tomography (CT) during hospitalization
after the surgical procedure. A positive thromboembolic
complication was determined by review of all charts for
diagnostic tests that would be used to diagnose thrombo-
embolic complications, such as ultrasound or spiral
CT. Clinicians caring for the patients were not given
access to the ROTEM results, and routine anticoagu-
lation regimens were used as directed by the clini-
cians. No additional tests were ordered to evaluate for
thromboembolic complications.Data and sample collection
Two milliliters of whole blood was collected for ROTEM
analysis from preoperatively drawn blood that was left
over from blood sent for routine scheduled laboratory
tests and would otherwise have been discarded (waste
blood). The blood was immediately filled into a citrated
tube and ROTEM analysis was performed within 60 mi-
nutes. Of note, ROTEM results have been shown to be
reproducible using blood samples stored up to 120 mi-
nutes at room temperature [6], and potentially longer.
Medical records were reviewed for patient demogra-
phics, surgical procedure, preoperative laboratory test
results including international normalized ratio (INR),
partial thromboplastin time (PTT) and platelet count,
ICU and hospital length of stay (LOS), and radiolo-
gical and/or clinical evidence of a thromboembolic
complication.ROTEM analysis
Coagulability was assessed using the ROTEM throm-
boelastometry analyzer (Tem Systems Inc.®, Munich,
Germany). A detailed description of the ROTEM tech-
nology has been published previously [7]. Extrinsic
rotational thromboelastometry (EXTEM), intrinsic ro-
tational thromboelastometry (INTEM), and fibrinogen
rotational thromboelastometry (FIBTEM) tests were
displayed on each blood sample. Each ROTEM test
requires approximately 300 microliters of citrated whole
blood. All samples in this study were processed within less
than one hour after collection, given that ROTEM results
are unchanged for citrated samples stored at room
temperature for up to 2 hours [6] and potentially as long
as up to six hours [8]. Quality control tests were run every
week using normal and abnormal control plasma samples
with known output parameters.
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ROTEM results were analyzed two ways. First, clotting
time, clot formation time (CFT), alpha angle (α), clot
firmness at 10 minutes (A10), and maximum clot firm-
ness (MCF) for each of intrinsic rotational thromboelasto-
metry (INTEM), extrinsic rotational thromboelastometry
(EXTEM), and fibrinogen rotational thromboelastometry
(FIBTEM) were compared between patients with and
without postoperative thromboembolic complications,
using Student’s t-test or the Mann-Whitney (Wilcoxon
rank) test (using α <0.05). Comparisons and correlations
between groups were made by the unpaired t-test or
Pearson’s test for correlation between values with a
Gaussian distribution and by the Mann-Whitney test
or Spearman’s test for correlation between continuous
variables without normal distribution. Gaussian distri-
bution was determined using Levene’s test for unequal
variance. Categorical data were compared using the
Chi-square or Fisher exact test. P-values were two-tailed
and P <0.05 was considered significant.
Receiver operating characteristic (ROC) curves were
plotted [9] and the point on the ROC curve closest to
sensitivity = specificity =1 was considered the best cutoff
value. We additionally calculated the Youden index
(sensitivity + specificity −1) and used the largest Youden
index as another best cutoff value. The area under the
curve (AUC) of the ROC curve was estimated using
Mann-Whitney statistics with associated Wald 95% confi-
dence intervals.
The MCF is the most commonly used parameter to
detect hypercoagulability [10], and is analogous to
maximum amplitude (MA) in the TEG [11,12]. We
compared the MCF for each of EXTEM, INTEM, and
FIBTEM to established reference values for the general
population [8]. A test was defined as hypercoagulable if
the patient’s MCF was greater than that of the 97.5th
percentile of the general population, that is, above the
reference range. Reference values are depicted in Table 1,
second column. There are no reliable reference values
described for FIBTEM α and A10, therefore we excluded
these variables. We defined hypercoagulability by an ap-
propriate MCF with any single test, with any two out of
three tests, or with EXTEM activator. We then used the
Chi-square test (α <0.05) to examine whether patients
who were preoperatively hypercoagulable by ROTEM had
higher rates of postoperative thromboembolic complica-
tions than those who were not.
SPSS 11.0.4 (SPSS Inc., Chicago, IL, USA) and Graphpad
Prism 4.0 (San Diego, CA, USA) software were used for
the statistical analysis.
Results
We enrolled and successfully performed ROTEM analysis
on 318 patients undergoing major non-cardiac surgerybetween April and August 2012. Of these, five patients
were excluded from the final analysis. Two patients chose
not to participate in the study and one patient underwent
an operation that did not constitute major surgery (un-
complicated shoulder arthroscopy). One patient’s hospital
records were insufficient for determination of whether or
not she had suffered any thromboembolic events, and one
patient’s radiologic examination could not definitively
determine whether the patient’s thromboembolic compli-
cation occurred before or after surgery.
Of the 313 included patients, 10 (3.2%) suffered throm-
boembolic complications prior to their discharge from the
hospital. These included six patients with isolated deep
vein thrombosis, three patients with deep vein thrombosis
further complicated by pulmonary embolism, and one
patient who developed both a common femoral artery
aneurysm thrombosis and a thrombosis of a vascular cath-
eter. One patient died as a direct result of his pulmonary
embolism. The thromboembolic complications occurred
between 1 and 17 days after surgery (median 5 days, inter-
quartile range: 1.8 to 7.25 days). With the exception of
one patient who developed a thromboembolic complica-
tion on postoperative day one, all received standard post-
operative thromboembolic prophylaxis. Four patients
received 40 mg enoxaparin subcutaneously once a day
and five patients received 5000 IU heparin subcutaneously
three times daily from the day of surgery up to the day
when the thromboembolic complication was diagnosed.
Patient demographic information and standard coagu-
lation studies (PTT, INR, platelet count) are summarized
in Table 2. Standard coagulation studies represent the un-
weighted average of all such tests taken on postoperative
day zero. Previously, standard coagulation studies have
been correlated with ROTEM parameters, for example in
patients undergoing major surgery with hemorrhage [13].
In patients who developed coagulopathy and bleeding,
abnormal platelet counts, INR and fibrinogen levels corre-
lated well with EXTEM and INTEM, MCF and other
ROTEM values. However, the standard coagulation stud-
ies did not provide any indication of which patients might
be hypercoagulable. In our investigation, standard coagu-
lation studies, type of surgery, and patient demographic
factors were not significantly different in patients with
or without postoperative thromboembolic complications
(P >0.05 for all). Patients who suffered thromboembolic
complications had noticeably longer mean ICU LOS
(5.7 +/−9.7 versus 0.9 +/−3.4 days) and hospital LOS
(25.5 +/−32.4 versus 6.2 +/−7.8 days). However, these dif-
ferences were not statistically significant when no Gaussian
comparison was used (median (interquartile range) ICU
LOS: 2.5 (2 to 4) versus 0 (0 to 1) days, P >0.05; hospital
LOS: 11.5 (8.75 to 33.8) versus 5 (3 to 7) days, P >0.05).
There was no significant difference between patients
with and without thromboembolic complications with
Table 1 Preoperative rotational thromboelastometry (ROTEM) parameters
ROTEM parameter Normal values No thromboembolic complication
(n =303), mean (SD)
Thromboembolic complication
(n =10), mean (SD)
P-value AUC ROC
EXTEM
Clotting time, s 42 to 74 55.1 (31.2) 48.7 (16.9) 0.19 ---
Clot formation time, s 46 to 148 87.1 (61.7) 58.5 (16.6) <0.001 0.74
Alpha angle, degrees 63 to 81 74.3 (6.9) 78.4 (3.1) 0.002 0.70
Amplitude at 10/20 minutes, mm 50 to 69 58.2 (8.7) 64.0 (5.4) 0.008 0.72
Maximum clot firmness, mm 49 to 71 65.0 (7.5) 70.4 (5.2) 0.009 0.73
INTEM
Clotting time, s 137 to 246 171.5 (34.1) 165.8 (24.6) 0.11 ---
Clot formation time, s 71 to 82 72.2 (57.3) 51.0 (11.4) <0.001 0.75
Alpha angle, degrees 52 to 72 76.5 (5.5) 79.4 (2.4) 0.006 0.72
Amplitude at 10/20 minutes, mm 137 to 246 56.7 (7.8) 63.0 (5.8) 0.012 0.75
Maximum clot firmness, mm 52 to 72 62.8 (7.1) 68.6 (6.0) 0.02 0.74
FIBTEM
Clotting time, s 43 to 69 53.3 (47.4) 44.7 (13.1) 0.11 ---
Clot formation time, s 339.9 (366.5) 378.9 (606.0) 0.12 ---
Alpha angle, degrees 73.6 (6.6) 77.0 (5.4) 0.085 ---
Amplitude at 10/20 minutes, mm 8 to 21 16.5 (6.8) 23.7 (11.2) 0.010 ---
Maximum clot firmness, mm 9 to 25 17.8 (7.6) 24.8 (11.2) 0.015 ---
For significant predictive tests, the area under the curve (AUC) of the receiver operating characteristic (ROC) curve is listed. EXTEM, extrinsic rotational thromboelastometry;
INTEM, intrinsic rotational thromboelastometry; FIBTEM, fibrinogen rotational thromboelastometry; ns, not significant.
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surgery) or the presence of preoperative end-stage
renal disease (ESRD) or cancer as a cause for surgery
(Table 2).
ROTEM analysis
ROTEM results for patients who did and did not have
thromboembolic events are shown in Table 1 and Figure 1.
Based on the results of Levene’s test for equality of vari-
ance, unequal variance between patients with and without
thromboembolic complications was assumed.
Patients with ESRD had smaller α in EXTEM
(ESRD versus no ESRD: EXTEM α: 78.1 +/−5.8° versus
74.2 +/−6.9°, P <0.05; mean +/−SD). The other ROTEM
variables were not significantly different.
When comparing patients with and without throm-
boembolic complications, clotting time did not differ
significantly using any of the three activators (P >0.05).
For both EXTEM and INTEM, CFT was significantly
lower in patients who suffered thromboembolic com-
plications (P <0.001 for both). For both EXTEM and
INTEM, α, A10 and MCF were higher in patients with
than without thromboembolic complications (P <0.05 to
P <0.01). Results using FIBTEM showed similar trends
but were not statistically significant.
There was no difference in the incidence of TEC
between patients with and without obesity (body massindex (BMI) >30 m/kg2 (Table 2)). However, obese pa-
tients (n =102) had larger A10 and MCF in EXTEM (A10:
59.8 +/−8.6 versus 57.7 +/−8.7, P <0.05; MCF: 66.5 +/−6.8
versus 64.5 +/−7.7, P <0.05) and larger MCF in INTEM
(64.2 +/−6.2 versus 62.4 +/−7.5, P <0.05).
ROC curves were plotted for EXTEM and INTEM
CFT, α, A10 and MCF. The AUC for these curves are
shown in Table 1. INTEM A10 had the largest area
under the curve of 0.75. When defining the best cutoff
as the point on the ROC curve closest to sensitivity =
specificity =1, the best cutoff of INTEM A10 to predict
thromboembolic complications was 61.5 mm with a spe-
cificity =76.3 (95% CI 70.9% to 81.2%), a sensitivity =66.7
(95% CI 29.9% to 92.51%) and a positive predictive
value =8% (95% CI 3.0 to 17.0%) and a negative pre-
dictive value =98.0 (95% CI 96.1 to 0.99.7%) and a
likelihood ration =2.816. The best cutoff using the
largest Youden index (sensitivity + specificity −1) was
64.5 mm with a specificity =87.6 (95% CI 83.2% to 91.2%)
and a sensitivity =55.6 (95% CI 21.2% to 86.3%) and
positive predictive value =12.5 (95% CI 4.2 to 26.8%) and a
negative predictive value =98.4 (95% CI 96.0 to 0.99.6%)
and a likelihood ration =4.492. The ROC curve for INTEM
A10 is shown in Figure 2.
Hypercoagulability, defined by an MCF above the upper
limit of the normal reference values (97.5th percentile of
the general population), occurred significantly more often
Table 2 Patient demographics, outcomes and standard coagulation studies





Age, years 58.7 (+/−15.2) 58.5 (+/−15.2) 63.6 (+/−16.1) 0.30
Body mass index, kg/m2 27.7 (+/−6.3) 27.8 (+/−6.3) 26.4 (+/−4.8) 0.49
Obesity 102 (32.6%) 99 (32.7%) 3 (30%) 0.57
Female 165 (53%) 161 (53%) 4 (40%) 0.88
Surgery class
Major abdominal 85 (27%) 81 (27%) 4 (40%) 0.47
Gynecological 4 (1%) 4 (1%) 0 (0%) 1.0
Central nervous system neurosurgery 48 (15%) 48 (16%) 0 (0% 0.37
Spine 62 (20%) 60 (20%) 2 (20%) 1.0
Vascular 11 (4%) 11 (4%) 0 (0%) 1.0
Urology 26 (8%) 23 (8%) 3 (30%) 0.04
Orthopedics 29 (9%) 29 (10%) 0 (0%) 0.60
Liver surgery 20 (6%) 19 (6%) 1 (10%) 0.49
Renal transplant 24 (8%) 24 (8%) 0 (0%) 1.0
Other 4 (1%) 4 (1%) 0 (0%) 1.0
Cancer 147 (47.0%) 141 (46.5%) 6 (60%) 0.62
End-stage renal disease 17 (5.4%) 17 (5.6%) 0 (0%) 1.0
Outcomes
ICU length of stay, days 1.1 (+/−3.8) 0.9 (+/−3.4) 5.7 (+/−9.7) 0.15
Hospital length of stay, days 6.8 (+/−10.1) 6.2 (+/−7.8) 25.5 (+/−32.4) 0.09
Myocardial infarction 3 (1%) 3 (1%) 0 (0%) 1.0
Acute kidney injury (RIFLE-risk) 12 (3.8%) 12 (3.9%) 0 (0%) 1.0
Standard postoperative coagulation studies
Prothrombin time, s 32.3 (+/−11.6) 32.3 (+/−11.8) 33.1 (+/−6.2) 0.89
International normalized ratio 1.20 (+/−0.24) 1.20 (+/−0.25) 1.28 (+/−0.11) 0.39
Platelet count 201 (+/−67) 201 (+/−68) 212 (+/−69) 0.63
Data are reported as mean and standard deviation or number and percentage, as appropriate. Obesity = body mass index >30 m/kg2. RIFLE, risk, injury, failure,
loss, end-stage renal failure; ns = not significant.
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true regardless of whether the definition of hypercoagu-
lability entailed one or two of the three tests as abnormal
or only EXTEM as abnormal (odds ratio (OR) =4.73, 5.22,
and 4.65, respectively; 95% CI <0.05 for all). These data
are summarized in Table 3.
Discussion
Our study found that preoperative ROTEM analysis may
be able to identify patients at increased risk of thrombo-
embolic complications after major surgery. Specifically,
patients with thromboembolic complications had signifi-
cantly different ROTEM patterns in EXTEM and INTEM,
although not in FIBTEM. A10, A20 and CFT using
the INTEM activator were the most reliable predictors
of thromboembolic complications, with good predictive
power. Patients who developed thromboembolic compli-
cation had, on average, decreased CFT and increased α,A10 and MCF compared to patients who did not develop
such complications.
These differences have previously been described as
signs of hypercoagulability by TEG [7] therefore enhan-
cing the biological plausibility of our results. Although
clotting time did not differ significantly between the two
groups, CFT, α and MCF together assay the same phase
of the clotting cascade: the formation of a stable clot
through the interaction of activated platelets and fibrin.
The clotting time, in contrast, is the only one of these
parameters that measures the first phase of the clotting
cascade: the time until fibrin formation. Similarly, stand-
ard clotting tests such as PTT and INR reflect the time
to fibrin formation only, and, like the clotting time, were
not different in patients with and without thrombo-
embolic complications.
The significant indices of hypercoagulability provided
by EXTEM and INTEM were not replicated by FIBTEM
Figure 1 Preoperative rotational thromboelastometry (ROTEM) parameters using extrinsic rotational thromboelastometry (EXTEM) and
intrinsic rotational thromboelastometry (INTEM) activators in patients with and without thromboembolic complications (TEC). Ex-CT,
EXTEM clotting time; IN-CT, INTEM clotting time; CFT, clot formation time; alpha, α angle; A10, amplitude at 10/20 minutes; MCF, maximum clot
firmness. *P <0.05.
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INTEM, FIBTEM evaluates only the fibrin contribution
to clot formation because it incorporates cytochalasin D,
a platelet inhibitor. Our findings therefore suggest that
tests such as EXTEM and INTEM, which include the
platelet contribution to clot formation, are better suited
to detect hypercoagulablity. They also enhance our appre-
ciation of the relevance of platelets to the development of
hypercoagulability and thromboembolic complications.
A recent meta-analysis by Dai et al. [14] highlights
several studies suggesting that TEG may be useful in pre-
dicting postoperative thromboembolism. However, the
authors emphasize the practical limitations of the original,Figure 2 Receiver operating characteristic curve for amplitude at
10 minutes (A10) using intrinsic rotational thromboelastometry
(INTEM) activator.labor-intensive TEG methodology, which may indicate
why many past studies included small sample sizes - often
100 patients or fewer, and sometimes as few as ten pa-
tients [15]. Larger studies often examined only patients
undergoing a specific operation [16,17]. Only one large
prospective study has examined the use of TEG in the
prediction of thromboembolic events in general surgery
[12] and found promising results that require further in-
vestigation. In contrast, ROTEM provides a number of ad-
vantages that render it much more practicable for routine
clinical use at the bedside or in the operating room. These
include a stable platform; standardized measuring tech-
nique; pathway sub-analysis; rapid, digitized, replicable





% of patients (n)
P-value
Increased MCF in 2 or 3 of 3 tests (INTEM/EXTEM/FIBTEM)
Hypercoagulable 11.5 (3)
Normal 2.4 (7)
Odds ratio 5.22 0.01
Increased MCF in at least 1 of 3 tests (INTEM/EXTEM/FIBTEM)
Hypercoagulable 8.6 (5)
Normal 2.0 (5)
Odds ratio 4.72 0.009
Increased MCF in EXTEM
Hypercoagulable 9.5 (4)
Normal 2.2 (6)
Odds ratio 4.65 0.01
INTEM, intrinsic rotational thromboelastometry; EXTEM, extrinsic rotational
thromboelastometry; FIBTEM, fibrinogen rotational thromboelastometry.
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based on the same general technology as TEG, it may pro-
duce different results and the devices cannot be assumed
to be interchangeable [18].
A few factors should be noted that may contribute to
noticeable differences in the incidence of thromboembolic
events in this study compared with previous studies using
ROTEM or TEG. We chose to include only clinically
evident thromboembolic complications; some previous
studies incorporated routine deep vein thrombosis screen-
ing of all participants. Our goal was to evaluate the clinical
applicability of routine ROTEM use, so we excluded sub-
clinical thrombotic events detected by screening tests that
might be implemented for study purposes only. We chose
not to evaluate thromboembolic risk scores, which iden-
tify patients at very high risk of thromboembolic compli-
cations and contain many variables that are not readily
ascertainable.
Columbia University Medical Center has standardized
protocols for thromboembolic prophylaxis, but we neither
assessed nor enforced compliance. While it is possible that
inadequate compliance may have increased thrombo-
embolic risk, nine out of the ten patients who developed
thromboembolic complications did so despite receiving
standard thromboembolic prophylaxis. Future studies
should be designed to assess not only if preoperative
ROTEM is useful to identify high-risk patients, but also
whether such patients might benefit from more aggressive
or alternative modes of thromboembolic prophylaxis.
Definitions of hypercoagulability are not uniformly
established and vary widely in studies using TEG. There
are also no clear cutoff values for hypercoagulability
when using ROTEM, although an increased MCF is con-
sidered the most reliable [10]. Our study confirms that
patients with abnormally increased MCF are at increased
risk for thromboembolic complications, and may facili-
tate the development of a standardized ROTEM defin-
ition of hypercoagulability. At the same time it must be
considered that the reference values for ROTEM have
been derived from a healthy volunteer population and
not a surgical population. Of note, 2.0 to 2.4% of patients
without thromboembolic complications had an MCF
higher than the reference value. This is consistent with
the definition of the reference value in which 2.5% of the
measurements are above the upper limit (97.5th percent-
ile). Nonetheless, the relationship of ROTEM parameters
to hypercoagulability remains circumstantial until eluci-
dated by further study. It also needs to be noted that only
half of patients with TEC had MCF values that were
within the normal limits and only five patients had MCF
values that were above the published norm. It will there-
fore be difficult to detect patients who will develop TECs
solely on the basis of ROTEM analysis. Future studies will
need to evaluate if inclusion of ROTEM analysis into abroader risk profile with sufficient precision to change
clinical management of patients at increased risk. As our
study was not designed or powered to establish a change
in clinical practice, larger and more focused studies are
needed before we can recommend changing thrombem-
bolic prophylaxis solely based on preoperative ROTEM
results. The etiology of thromboembolic complications is
complex and includes many more factors other than po-
tential inherited or acquired hypercoagulability. We mea-
sured ROTEM immediately prior to the surgical procedure
to better isolate the effect of hypercoagulability and
exclude the many intra- and postoperative factors that con-
tribute to the development of thromboembolic complica-
tions and may have affected ROTEM analysis.
Our study did not find that patients undergoing certain
classes of surgery or patients with cancer or ESRD had a
higher incidence of thromboembolic complications, but it
was not designed or powered to detect any possible differ-
ences. Interestingly, obese patients had larger MCF in
EXTEM and INTEM (and larger A10 in EXTEM). If this
is evidence of hypercoagulability associated with obesity
[19], this requires further study.
Conclusions
In summary, we observed that preoperative ROTEM
analysis may be able to identify patients undergoing
major non-cardiac surgery who are at increased risk for
postoperative thromboembolic events. Our study raises a
number of pertinent clinical questions. Can defined cri-
teria for hypercoagulability be established by ROTEM?
Can ROTEM identify whether high-risk patients could
benefit from more aggressive or alternate antithrombotic
regimens? How is ROTEM affected by specific inherited
or acquired hypercoagulable diseases? And, finally, is
routine use of ROTEM cost-effective in helping us to de-
crease the incidence of postoperative thromboembolic
complications?
Key messages
 Rotational thrombelastography using INTEM and
EXTEM prior to non-cardiac surgery is significantly
different in patients who develop postoperative
thrombembolic complications
 Patients with thrombembolic complications
specifically had significantly lower clot formation
time (CFT), higher alpha angle (α) and larger
maximum clot firmness (MCF)
 INTEM clot firmness at 10 minutes (A10) was the
best predictor of thromboembolic complications,
with an ROC area under the curve of 0.751
 Rotational thrombelastography may be able to
detect patients who are susceptible to postoperative
postoperative thrombembolic complications.
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